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The study aimed to compare the incidence of the pathogenic point mutation A3243G in the gene 
tRNA
Leu(UUR) 
indicating sub-type 2 diabetes mellitus conducted within the Nigerian population with that 
reported in other populations. 112 patients diagnosed with type 2 diabetes (T2D) mellitus according to 
the World Health Organization criteria were selected based on family history and re-evaluated for 
associated disorders from the diabetic clinics in the Northern part of Nigeria. The mtDNA of these 
patients was extracted and the tRNA
Leu(UUR) 
gene screened for A3243G by PCR-RFLP method. Probands 
with maternal history were further investigated for other mutations using PCR-sequencing methods. 
None of the 112 patients were found to carry the A3243G mutation in the mitochondrial tRNA
Leu(UUR) 
gene in the homoplasmic or in the heteroplasmic form. However, C3254T was identified in two of our 
patients. This mutation was reported to be associated with gestational diabetes and linked with 
population from sub-Saharan Africa. The A3243G mutation in mitochondrial tRNA
Leu(UUR) 
is not a 
frequent cause of maternal diabetes in the Nigerian population contrary to other reported populations. 
However, further screening of an enlarged selected study group is necessary to fully determine the 
prevalence of this mutation in this population. This further search will help to fully appreciate the 
prevalence of maternal inheritance and diabetic deafness (MIDD) as extensively reported in other 
populations. 
 








gene is a hot spot for 
pathogenic mutations and they are associated with 
mitochondrial diseases in various clinical features (Emna 
et al., 2007). The landmark discoveries of mitochondrial 
diabetes were the identification of a 10.4 kb deletion in 
mitochondrial DNA (mtDNA) associated with diabetes 
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mutation associated with diabetes and deafness in a 
large pedigree (Wei et al., 2006). Since then, numerous 
point mutations, deletions and duplications in mtDNA 
have been detected to associate with diabetes worldwide. 
Of these, the A3243G mutation appears to be the most 
common diabetes associated mtDNA mutation, 
accounting for between 0.5 and 3% of all type 2 diabetes 
(T2D) in various populations (Walker and Turnbull, 1997; 
Takashi et al., 1994; Wallace, 2005). This mutation, 
which is present in heteroplasmic form in patient cells, 
exhibited a remark-able variability of its clinical 
manifestation. When 70% of total  mtDNA in cells  carried   




the  A3243G  mutation,  this mutation does not cause 
diabetes, but instead causes more severe symptoms, 
including short stature, cardio-myopathy, mitochondrial 
encephalomyopathy, lactic acid and stroke-like episodes 
(MELAS) syndrome (Yu-ichi et al., 1990). When present 
at relatively low levels (10 to 30%) in the patient’s blood, 
the patients may manifest only diabetes with or without 
sensorineural hearing loss and it is now associated with 
maternal inheritance and diabetic deafness (MIDD) (Van 
den et al., 1992; Maassen, 2002; Ohkubo et al., 2001),
 
also known as maternal diabetes. The age at onset of 
diabetes in patients with the A3243G mutation varies, 
with average at the age of 35 years (Maassen et al., 
2002; Ohkubo et al., 2001). 
There is a growing body of evidence that the mito-
chondrial dysfunction plays a crucial role in the 
pathogenesis of type 2 diabetes. Also, evidences have 
shown that mtDNA abnormalities account for appro-
ximately 1% of all cases of diabetes (Maassen et al., 
2001). Point mutations in mtDNA (mitochondrial tRNA 
genes) are particularly frequent since over 100 
pathogenic mtDNA mutations were described in various 
tRNA genes. (MITOMAP: 
 Human Mitochondrial Genome Database, 
www.mitomap.org). While this mutation (A3243G) has 
been described in different populations with Caucasians 
as the majority of the study groups, there has been no 
documented evidence of this mutation among an 
unmixed population from the Sub-Saharan in Africa. This 
observation therefore prompted this study to test for this 
hypothesis: incidence of the pathogenic point mutation 
A3243G in the gene tRNA
Leu(UUR) 
indicating type 2 
diabetes mellitus is comparable within the Nigerian popu-
lation to that determined in other reported Caucasian 
population. Hence, this study to our knowledge may be 
the first documented evidence of A3243G mtDNA 
mutation from this part of the world. 
 
 
MATERIALS AND METHODS 
 
Study population  
 
112 type 2 diabetic patients according to the World Health 
Organization criteria (WHO consultation, 1999) with parental history 
only were selected from diabetic units of three hospitals located in 
the Northern part of Nigeria. Those that could not recall or were not 
sure of parental history of diabetes were excluded. Subjects 
identified for the study signed an informed consent form before they 
were allowed to participate. Ethical approval was gained from these 
hospitals- Sir Yaya Memorial Hospital, Yauri General Hospital and 
Apex Clinic. The selected patients were also re-evaluated for the 
following clinical characteristics: body mass index (BMI), systolic 
blood pressure (SBP), diastolic blood pressure (DBP), 
neurosensorial deafness, cardiomyopathy, stroke like episodes, 
retinopathy, foot disease and neuropathy. 
 
 
DNA extraction  
 





published protocol (Shazia et al., 2007). The extracted DNA 
samples were stored at -20°C before analysis. 
 
 
Polymerase chain reaction – restriction fragment length 
polymorphism (PCR-RFLP) 
 
The method and primers used to perform amplification of the gene 
of interest (tRNA
Leu(UUR)
) and part of NADH dehydrogenase subunit 
1 (ND1) located on mtDNA are the same as described by Emna et 
al. (2007) with the following modifications: the total reaction volume 
of 20 µL containing an average of 200 ng mtDNA, 10 pmol of each 
primer, 1.25 mM dNTPs, 5 × PCR buffer (GO TAQ
TM
, Promega 
Corporation, USA), 5 U of Taq DNA polymerase (GO TAQ
TM
, 
Promega Corporation, USA) and molecular grade water was 
amplified using Peltier thermal cycler (PTC-200, MJ Research Inc., 
Canada).  
The reaction generated PCR products of the gene tRNA
Leu(UUR) 
of 
528 bp only. Amplified products were confirmed by performing agar 
gel electrophoresis. The PCR products and unmethylated DNA 
lambda were digested with endonuclease restriction enzyme, ApaI 
separately. The total reaction volume of 20 µl containing Apa I (10 
U /µL), 10 × restriction buffer, PCR products or DNA lambda and 
molecular grade water was incubated at 37°C for 1 to 2 h for the 
digestion to occur. The reaction with the endonuclease enzyme and 
DNA lambda was the positive control and the one without the 
enzyme served as negative control. Furthermore, the sample and 
control digests were resolved on 2 and 0.8% agarose gel, 
respectively. Gels stained with ethidium bromide were placed on a 
UV light transilluminator and PCR and digested products were 




PCR sequencing  
 
Approximately, 10 ng of the purified PCR product from probands 
with maternal history only (using GENELUTE
TM
 PCR Clean-up Kit, 
Sigma-Aldrich, Inc.) was amplified in a total reaction volume of 20 
µL containing the Big Dye terminator reaction buffer, each of the 
primer (3.2 pmol/µL) and molecular grade water. This reaction was 
programmed to perform at 96°C for 1 min followed by 25 cycles of 
96°C for 10 s, 50°C for 5 s and 60°C for 4 min using the Peltier 
thermal cycler. The amplified gene in the reaction mix was 
precipitated after several alcohol washes at 95 and 70%, 
respectively dried using the vacuum centrifuge, resuspended in Hi-
Di formamide and loaded onto the 3500 Genetic Analyzer, Applied 
Biosystems for sequencing. The resultant sequences were 
compared with the Cambridge sequence (GenBank Accession No. 
NC_012920) (Andrews et al., 1999). 
 
 
Statistical analysis  
 
Epi info version 3.5.1 (CDC Atlanta, USA) was used to assess the 
effect of clinical characteristics on probands based on parental 





Effect of transmission pattern on clinical 
characteristics 
 
Out   of   the   1,110  patients   screened   for   maternally 




Table 1. Baseline characteristics of probands according to their parent’s diabetic status. The Data is presented as mean ± 




Paternal Maternal Bilineal 
Number 27 73 12 
Age at diagnosis 43.7 ± 10.9 44.5 ± 11.8 46.1 ± 10.1 
Age at examination 51.8 ± 8.4 52.1 ± 13.0 56.1 ± 11.5 
BMI (kg/m
2
) 27.7 ± 4.3 26.0 ± 6.2 27.5 ± 3.9 
SBP (mmHg) 136.3 ± 19.3 136.9 ± 24.6 138.8 ± 14.9 
DBP (mmHg) 81.0 ± 9.7 85.4 ± 12.0 82.2 ± 8.9 
Frequency of neurosensorial deafness (%) 7.4 7.0 0.0 
Frequency of cardiomyopathy (%) 37.0 43.5 50.0 
Frequency of stroke (%) 7.4 10.9 21.4 
Frequency of retinopathy (%) 74.1 60.9 71.4 
Frequency of diabetic foot disease (%) 7.4 6.5 7.1 




inherited T2D, 85 patients could recall the diabetic status 
of their mothers (grandmothers inclusive) and they were 
subsequently recruited for the study. 27 patients with 
diabetic fathers were also recruited but only served as 
controls. The influence of the transmission patterns of 
T2D on the clinical outcome of patients was divided 
according to the probands with diabetic mother only 
(maternal), diabetic father only (paternal) and diabetic 
mother and grandmothers (bilineal). Results show no 
significant difference in clinical presentations between the 
controls, maternal and bilineal (Table 1). The ANOVA p-
value of these presentations was >0.05 which is not 
statistically significant; no significant differences between 
family groups. However, maternal excess is 2.7; where it 
is expressed as the ratio of affected mothers to affected 









from all the patients was 
screened for the presence of A3243G mutation  by  PCR- 
RFLP. The A3243G mutation created a restriction ApaI 
site and the digestion resulted in two fragments of 234 
and 294 bp (as compared with the molecular markers-
100 bp DNA ladder) if the mutation is present, whereas in 
the absence of this mutation, a 528 bp fragment 
corresponding to the PCR product should be observed 
(Figure 1). Results were compared with the molecular 
markers and evidence to show that ApaI can create a 
restriction site (restricted DNA lambda) was proven. ApaI 
created a restricted site of the DNA lambda at position 
10,090 bp thereby generating two bands of 10,090 and 
39,000 bp, respectively (positive control), while the DNA 
lambda was uncut without the ApaI as 49,000 bp 
(negative control) (Figure 2). All the results from the 112 
patients were compared with these controls.  
More also, results were further determined by visual 
inspection of the size of fragments with the molecular 
markers as a reference and the restricted DNA lambda 
as a proof of the functional activity of the endonuclease 
enzyme. It was observed that none of the 112 patients 
were found to carry the A3243G mutation in the 
mitochondrial tRNA
Leu(UUR) 
gene in the homoplasmic or in 
the heteroplasmic form. Therefore, we confirm the 
absence of the A3243G mutation in this gene. 
Furthermore, the tRNA
Leu(UUR) 
gene of the patients with 
maternal history only were further screened for mutations 
using direct sequencing in order to identify different 









 gene of patients with maternal history 
were screened for mutations by comparing their 
sequences with the annotated human mitochondrial 
genome database in order to identify different mutation 
from A3243G. The visual inspection identified one single 
nucleotide polymorphism (C3254A) from 2 patients with 
these identity; 37/10 and 45/10. C3254A is indicated in 






It has been well documented that maternal inheritance 
has been implicated with the diagnosis of T2D. 
Therefore, the maternal excess reported in this study is 
not different from most published studies on maternally 
inherited T2D (Alcolado and Alcolado, 1991; Lin et al., 
1994; Young et al., 1995; Karter et al., 1999; Bjornholt et 
al., 2000). The recent publication in Tunisia reported  that 






Figure 1. Screening of the A3243G mutation by PCR-RFLP. PCR fragment of 
528 bp was digested with Apa I. The wild type PCR product does not contain 
the ApaI restriction site but PCR product with A3243G is expected to cleave 
into two fragments of 234 and 294 bp. Hence, Lanes 2 to 10 is a 
representation of restriction assay in patient’s samples that resulted in an 







Figure 2. Restriction digestion of unmethylated lambda DNA. Lane A 
represents the cut DNA; ApaI digested the lambda DNA into two fragments 
(10,090 and 39,000 bp, respectively), but remained uncut in Lane B in the 




patients with T2D are more likely to have an affected 
mother than their father (Imen et al., 2007) which is the 
same with the South Africa study (Erasmus et al., 
2001).The two studies from Africa did not however 
evaluate the contribution of mitochondrial tRNA
Leu(UUR) 
in 
the transmission of maternally inherited T2D which has 
been well reported from Europe, America and Asia. To 
our knowledge, our documented data is likely to be the 
first in this region to further document the association of 
tRNA
Leu(UUR) 
mutations (particularly A3243G) with T2D as 
reported in studies not from Africa.  
Our observation showed the absence of this mutation 
among the patients studied. This finding was also 
observed among the studied polish population (Maclej et 
al., 2001).This study and the polish studies examined 
probands with positive family history, maternal and 
paternal inclusive. Also, among the 128 patients 
screened for  A3243G  in  the  Tunisian  study, none  was  
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found with the mutation, although, only 30 
diabetics contributed to the study (Emna et al., 
2007). It was however, not mentioned if these 
diabetics were type 1 or type 2 but there were 
classical features of MIDD or MELAS in some of 
the patients evaluated. The finding of this study is 
in contrast to majority of studies conducted among 
the Caucasians with varied frequencies. The 
prevalence of less than 1% was documented 
among the studied Brazilian, Australian, Korean 
and British (Daisy et al., 2008; Carolyn et al., 
2007; Hyun et al., 1997; Newkirk et al., 1997), 
while a prevalence of 4.1% was documented 
among the Japanese, 2.6, 2.9 and 1% were 
reported among the Scandinavian, Finish and 
Hong Kong, respectively (Suzuki et al., 2003; 
Odawara et al., 1995; Uchigata et al., 1996; Lehto 
et al., 1999; Kari et al., 1998; Ng et al., 2000). The 
studied Brazilian population was made up of 344 
Caucasoid and 101 African-Brazilians. This 
population was classified into classical type 2 
diabetes mellitus (without MIDD) and type 2 
diabetes mellitus (with MIDD). The identified 
patients with A3243G belonged to the second 
group. In addition, these patients presented with 
age at diagnosis, before 30 years, BMI <25kg/m
2
, 
insulin treatment, and presence of proliferative 
retinopathy and ischemic cardiomyopathy (Daisy 
et al., 2008). 
This is however different from the Australian 
study, that studied a large cohort of individuals 
without screening for diabetes mellitus within a 
defined urban area. The identified 7 patients with 
A3243G were previously undiagnosed, oligo-
symptomatic and were thought to have age-
related hearing loss (Carolyn et al., 2007). Also, 
out of the 1,440 patients diagnosed as type1 and 
type 2 diabetes in the British study, 445 had one 
or more features of MIDD and/or MELAS. Only 2 
of this group of patients had this mutation, 
A3243G (Newkirk et al., 1997). While the Korean 
study randomly screened patients irrespective of 
their diabetic types. The proband identified with 
A3243G had history of myoclonic epilepsy, mild 
sensorineural hearing loss, one year duration of 
diabetes mellitus and a low level C peptide 
response to oral glucose (Hyun et al., 1997). In 
addition, the Japanese study, attributed poly-
neuropathy, earlier onset of diabetes and a higher 
frequency of retinopathy, nephropathy and insulin 
therapy as mostly found among type 2 diabetic 
patients with A3243G mtDNA mutation with the 11 
identified patients. This mutation A3243G has 
been well documented in the Japanese population  




(Suzuki et al., 2003; Odawara et al., 1995; Uchigata et 
al., 1996) and appears to be more prevalent than in any 
other population. 
Unlike the Japanese study, however, Scandinavian 
study focused on maturity onset diabetes of the young 
and mitochondrial genes to early onset diabetes with a 
strong family history of diabetes in a cohort with a high 
prevalence of type 1 diabetes mellitus. However, the 3 
identified MIDD patients with A3243G resembled more 
the phenotype of the insulin resistant type 2 diabetic 
patients (Lehto et al., 1999). While the Hong Kong 
Chinese classified the patients into early (133) and late 
onset (348) and all were diagnosed as having type 2 
diabetes mellitus, 4 of the early onset patients carried the 
mutation with maternal family history, while 1 of the late 
onset patients carried the mutation but without the history 
(Ng et al., 2000). Unlike the other studies, the Finish 
study examined a large population but 480 samples were 
analyzed for A3243G based on clinical presentations of 
the patients. The 14 identified patients with the mutation 
presented with diabetes, hearing loss, hypertrophic 
cardiomyopathy, occipital stroke, ophthalmoplegia and 
epilepsy (Kari et al., 1998). In all the identified studies, 
study approaches in the identification of the mutation 
varied from one group to another, although, there were 
similarities in some studies. One common factor with all 
the mentioned studies is the high number of subjects 
recruited unlike our study. This may be one of the 
reasons responsible for the absence of the mutation in 
our study. Hence, this may require a further screening of 
an enlarged selected probands. However, our study 
documented some of the common co-morbidities 
associated with diabetes and one or two of classical 
symptoms of MIDD like in the Finish, Japanese, Korean 
and Brazillian studies.  
It is also possible that the blood sample used as the 
source of the mtDNA could have contributed to non-
detection of the mutation. This is because different 
samples like blood, hair follicles, buccal epithelial cells 
and muscle biopsy have been used to determine the 
presence of A3243G mutation (Kari et al., 1998; Chia-
Wei et al., 2001) but it has been shown that the 
proportions of mutant mtDNA A3243G in diabetic 
subjects were noted to be the highest in muscle tissue 
followed by hair follicles and lowest in blood cells (Chia-
Wei et al., 2001). Interestingly, the proportions of this 
mutation in all the tissues were found to decline with 
increase in age (Chia-Wei et al., 2001) suggesting that 
our study must have missed the mutation of interest since 
the average age of studied subjects at examination was 
approximately 52 years.  
This study detected C3254A mutation from two of the 
patients investigated in this work, a mutation that has 
been reported in the MITOMAP and associated with 
gestational diabetes mellitus (Chen et al., 1999) but this 
mutation need to be further investigated for its functional 





that carried this mutation in this study presented with 
diabetic retinopathy and neuropathy which are symptoms 
usually associated with T2D. Interestingly, this mutation 
has also been recognized to be associated with the Sub-
Saharan Africans (non-Khoisan) (Behar et al., 2008b) 
confirming where the sample collection was done. It can 
be argued that the mutation associated with gestational 
diabetes mellitus as reported by Chen et al may actually 
be “accidental” since the parental history was not 
documented unlike this study. Though the geographical 
place where the samples were collected was not 
mentioned by Chen et al., (2000) it may be suggested 
that this mutation is associated with people from Sub-
Saharan Africa based on the human mtDNA phylogeny 
(PhyloTree.org-Global human mtDNA phylogenetic tree), 
or it is also possible that this mutation identified by Chen 
et al may have come from a patient from Sub-Saharan 
Africa as a result of migration. Since the authors 
considered this mutation novel and the functionality is yet 
to be established, it can then be suggested that this 
mutation is associated with the population in Sub-





Further screening is required to fully determine whether 
A3243G mutation contributes to the existence of T2D 
among the black race.  
This, along with the search of other pathogenic 
mitochondrial DNA mutations, will determine whether the 
gene, tRNA
Leu(UUR) 
is a hot spot as reported in the black 
community. Also, the further search will allow an 
understanding of the molecular background of diabetes in 
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